A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain
- Julie A. O'Brien,
- Wei Lemaire,
- Marion Wittmann,
- Marlene A. Jacobson,
- Sookhee N. Ha,
- David D. Wisnoski,
- Craig W. Lindsley,
- Hervé J. Schaffhauser,
- Blake Rowe,
- Cyrille Sur,
- Mark E. Duggan,
- Douglas J. Pettibone,
- P. Jeffrey Conn and
- David L. Williams, Jr.
- Neuroscience-WP, Merck Research Laboratories, West Point, Pennsylvania (J.A.O., W.L., M.W., M.A.J., C.S., D.J.P., D.L.W.); Molecular Systems, Merck Research Laboratories, Rahway, New Jersey (S.N.H.); Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania (D.D.W., C.W.L., M.E.D.); Neurobiology, Merck Research Laboratories, San Diego, California (H.J.S.); Molecular Neuroscience, Merck Research Laboratories, San Diego, California (B.R.); and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (P.J.C.)
- Address correspondence to:
Dr. David L. Williams, Jr., WP46-300, Merck Research Laboratories, West Point, PA 19486. E-mail: david_williams1{at}merck.com
Abstract
We found that N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA), is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). CPPHA alone had no agonist activity and acted as a selective positive allosteric modulator of human and rat mGluR5. CPPHA potentiated threshold responses to glutamate in fluorometric Ca2+ assays 7- to 8-fold with EC50 values in the 400 to 800 nM range, and at 10 μM shifted mGluR5 agonist concentration-response curves to glutamate, quisqualate, and (R,S)-3,5-dihydroxyphenylglycine (DHPG) 4- to 7-fold to the left. The only effect of CPPHA on other mGluRs was weak inhibition of mGluR4 and 8. Neither CPPHA nor the previously described 3,3′-difluorobenzaldazine (DFB) affected [3H]quisqualate binding to mGluR5, but although DFB partially competed for [3H]3-methoxy-5-(2-pyridinylethynyl)pyridine binding, CPPHA had no effect on the binding of this 2-methyl-6-(phenylethynyl)-pyridine analog to mGluR5. Although the binding sites for the two classes of allosteric modulators seem to be different, these different allosteric sites can modulate functionally and mechanistically similar allosteric effects. In electrophysiological studies of brain slice preparations, it had been previously shown that activation of mGluR5 receptors by agonists increased N-methyl-d-aspartate (NMDA) receptor currents in the CA1 region of hippocampal slices. We found that CPPHA (10 μM) potentiated NMDA receptor currents in hippocampal slices induced by threshold levels of DHPG, whereas having no effect on these currents by itself. Similarly, 10 μM CPPHA also potentiated mGluR5-mediated DHPG-induced depolarization of rat subthalamic nucleus neurons. These results demonstrate that allosteric potentiation of mGluR5 increases the effect of threshold agonist concentrations in native systems.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
DOI: 10.1124/jpet.103.061747.
-
ABBREVIATIONS: mGluR, metabotropic glutamate receptor; GPCR, G protein-coupled receptor; MPEP, 2-methyl-6-(phenylethynyl)-pyridine; DFB, 3,3′-difluorobenzaldazine; CPPHA, N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; LC/MS, liquid chromatography/mass spectrometry; TFA, trifluoroacetic acid; CHO, Chinese hamster ovary; methoxy-PEPy, 3-methoxy-5-(2-pyridinylethynyl)pyridine; STN, subthalamic nucleus; ACSF, artificial cerebrospinal fluid; NMDA, N-methyl-d-aspartate; DHPG, (R,S)-3,5-dihydroxyphenylglycine; FLIPR, fluorometric imaging plate reader; 4C3HPG, 4-carboxy,3-hydroxyphenylglcyine; PPI, prepulse inhibition; QX314, N-(2,6-dimethylphenylcarbamoylmethyl)triethylammonium bromide; SIB-1893, 2-methyl-6-(phenylethynyl) pyridine hydrochloride; PHCCC, N-phenyl-7-(hydroxylimino)cyclopropa[b]chromen-1a-carboxyamide; RO 67-7476, 2-(4-fluorophenyl)-1-[(4-methylphenyl)sulfonyl]pyrrolidine.
-
- Received October 17, 2003.
- Accepted January 26, 2004.
- The American Society for Pharmacology and Experimental Therapeutics



